AstraZeneca scores again: Calquence approved for CLL as BTK race heats up
Six months after first boasting about Phase III data, AstraZeneca has earned expanded FDA approval for its BTK inhibitor Calquence. The drug will now be …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.